Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


User Fee Draft Suggests Congressional Wariness Of Trump Budget

Executive Summary

Discussion draft includes US FDA negotiated user fee amounts well short of the total in recent Trump budget outline.

You may also be interested in...

First Draft FDA User Fee Bill Is Squeaky Clean

House and Senate release discussion draft of user fee reauthorization legislation that does not include any additional policy or practice changes for US FDA, though they may arrive later.

PDUFA First: Fees To Support Device Center Staff

To enhance combination product reviews, drug fee revenue will pay for related positions in CDRH.

PDUFA Fees Forced Down For FY 2017 Due To Refund Provision

Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts